394 related articles for article (PubMed ID: 31417879)
1. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
[TBL] [Abstract][Full Text] [Related]
2. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.
Schuster JE; Cox RG; Hastings AK; Boyd KL; Wadia J; Chen Z; Burton DR; Williamson RA; Williams JV
J Infect Dis; 2015 Jan; 211(2):216-25. PubMed ID: 24864121
[TBL] [Abstract][Full Text] [Related]
3. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.
Caidi H; Miao C; Thornburg NJ; Tripp RA; Anderson LJ; Haynes LM
Antiviral Res; 2018 Jun; 154():149-157. PubMed ID: 29678551
[TBL] [Abstract][Full Text] [Related]
4. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.
Chargelegue D; Obeid OE; Hsu SC; Shaw MD; Denbury AN; Taylor G; Steward MW
J Virol; 1998 Mar; 72(3):2040-6. PubMed ID: 9499058
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
[TBL] [Abstract][Full Text] [Related]
6. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.
Crowe JE; Gilmour PS; Murphy BR; Chanock RM; Duan L; Pomerantz RJ; Pilkington GR
J Infect Dis; 1998 Apr; 177(4):1073-6. PubMed ID: 9534985
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.
Haynes LM; Tonkin J; Anderson LJ; Tripp RA
J Virol; 2002 Jul; 76(14):6873-81. PubMed ID: 12072488
[TBL] [Abstract][Full Text] [Related]
8.
van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
[TBL] [Abstract][Full Text] [Related]
10. Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.
Jacque E; Chottin C; Laubreton D; Nogre M; Ferret C; de Marcos S; Baptista L; Drajac C; Mondon P; De Romeuf C; Rameix-Welti MA; Eléouët JF; Chtourou S; Riffault S; Perret G; Descamps D
Front Immunol; 2021; 12():683902. PubMed ID: 34163482
[TBL] [Abstract][Full Text] [Related]
11. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
[TBL] [Abstract][Full Text] [Related]
12. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.
Gimenez HB; Chisholm S; Dornan J; Cash P
Clin Diagn Lab Immunol; 1996 May; 3(3):280-6. PubMed ID: 8705669
[TBL] [Abstract][Full Text] [Related]
15. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.
Mejías A; Chávez-Bueno S; Ríos AM; Saavedra-Lozano J; Fonseca Aten M; Hatfield J; Kapur P; Gómez AM; Jafri HS; Ramilo O
Antimicrob Agents Chemother; 2004 May; 48(5):1811-22. PubMed ID: 15105140
[TBL] [Abstract][Full Text] [Related]
16. Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries.
Nguyen H; Hay J; Mazzulli T; Gallinger S; Sandhu J; Teng Y; Hozumi N
Clin Exp Immunol; 2000 Oct; 122(1):85-93. PubMed ID: 11012623
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.
Crowe JE; Murphy BR; Chanock RM; Williamson RA; Barbas CF; Burton DR
Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1386-90. PubMed ID: 8108420
[TBL] [Abstract][Full Text] [Related]
18. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
[TBL] [Abstract][Full Text] [Related]
19. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.
Mejías A; Chávez-Bueno S; Ríos AM; Aten MF; Raynor B; Peromingo E; Soni P; Olsen KD; Kiener PA; Gómez AM; Jafri HS; Ramilo O
Antimicrob Agents Chemother; 2005 Nov; 49(11):4700-7. PubMed ID: 16251314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
